Clinical trial results found that a majority of patients with atopic dermatitis who were treated with Ebgylss achieved ...

Eli Lilly (NYSE:LLY) saw a notable 10% increase in its stock price over the last month, driven by several important events.

Eli Lilly (NYSE:LLY) on Friday said that its recently approved eczema therapy Ebglyss led to complete skin clearance in 50% ...

After scoring a long-awaited FDA approval last fall, Eli Lilly has launched a consumer-facing campaign to get the word out ...

New results show Eli Lilly (LLY) and Company’s Ebglyss achieved deep and sustained response for patients with moderate-to-severe atopic ...

Ebglyss (lebrikizumab-lbkz) is a prescription drug used to treat atopic dermatitis in certain situations. Ebglyss comes as a liquid solution that you inject under your skin. Ebglyss is used in ...

Lilly added that the study also showed Ebglyss was able to achieve meaningful improvements in patients with ...

NHS England has been cleared to allow prescribing of Almirall’s Ebglyss for some people with atopic dermatitis, giving them the option of a therapy that only needs to be injected once a month.

Discover the latest industry insights at the 2025 Annual Meeting through engaging educational and product-focused sessions. These presentations give exhibiting companies a platform to unveil ...

He told Reuters that investments made over the past two years should imminently start to bear fruit, expecting its new eczema product Ebglyss to bring in 450 million euros ($472 million ...

Almirall SA (LBTSF) reports a robust 10.2% net sales increase and exceeds EBITDA projections, driven by key products Ilumetri and EBGLYSS.